Raptor Pharmaceutical Announces FDA Acceptance of NDA for RP103 for the Potential Treatment of Nephropathic Cystinosis

Raptor Pharmaceutical announced that the FDA has accepted for filing its new drug application (NDA) for its investigational drug candidate, cysteamine bitartrate delayed-release capsules (RP103), for the potential treatment of nephropathic cystinosis.
MarketWatch